Hybrid Protein Developed as Tools for Gene Cutting, Editing
|
By LabMedica International staff writers Posted on 23 Sep 2010 |
A U.S. team of researchers has developed a kind of hybrid proteins that can make double-strand DNA breaks at specific sites in living cells, potentially leading to better gene replacement and gene editing therapies.
Dr. Bing Yang, assistant professor of genetics, development and cell biology at Iowa State University (ISU; Ames, USA;), and his colleagues developed the hybrid protein by joining parts of two different bacterial proteins. One is called a TAL (transcription activator-like) effector, which functions to find the specific site on the gene that needs to be cut, and the other is an enzyme called a nuclease that cuts the DNA strands. Dr. Yang hopes this study will lead to the ability to engineer genomes by cutting out defective or undesirable parts of DNA, or by replacing defective or undesirable gene segments with a functioning piece of replacement DNA--a process called homologous recombination.
Dr. Yang reported that these hybrid proteins could be constructed to locate specific segments of the DNA in any sort of organism. "This breakthrough could eventually make it possible to efficiently modify plant, animal and even human genomes,” said Dr. Yang. "It should be effective in a range of organisms.”
The proteins function by binding onto the specific segment of DNA the researcher needs to change. These proteins do this by reading the DNA sequence and finding the specific area to be cut. Once the protein binds onto the DNA at the correct spot, the other half of the protein then cuts the double-stranded DNA. Bad or undesirable DNA can be resected and good or more desirable DNA can be introduced. When the DNA heals, the good DNA is included in the gene.
Dr. Yang began his project approximately one year ago after seeing the results of research by Dr. Adam Bogdanove, ISU associate professor of plant pathology, showing that TAL effectors use a very clear-cut code to bind to a specific DNA sequence. This discovery allowed Dr. Yang to predict precisely where the TAL effector nuclease will bind on the DNA to make the cut. Another study had similar results.
The conecept has also been validated by Dr. Bogdanove and Dr. Dan Voytas, collaborator in genetics, development, and cell biology at Iowa State, and director of the Center for Genome Engineering at the University of Minnesota (Twin Cities, USA). The TAL effector-nuclease approach improves on tools currently available for genome modification. It should be faster and less expensive to make TAL effector nucleases, and simpler to design them to recognize specific DNA sequences, according to Dr. Yang.
Yang's findings appeared in August 2010 in the online version of the journal Nucleic Acids Research. Dr. Voytas' and Bogdanove's study also appeared in August 2010 the journal Genetics. Dr. Voytas and Dr. Bogdanove were also able to demonstrate that the TAL effector part of the hybrid protein can be modified to target new DNA sequences.
Related Links:
Iowa State University
Dr. Bing Yang, assistant professor of genetics, development and cell biology at Iowa State University (ISU; Ames, USA;), and his colleagues developed the hybrid protein by joining parts of two different bacterial proteins. One is called a TAL (transcription activator-like) effector, which functions to find the specific site on the gene that needs to be cut, and the other is an enzyme called a nuclease that cuts the DNA strands. Dr. Yang hopes this study will lead to the ability to engineer genomes by cutting out defective or undesirable parts of DNA, or by replacing defective or undesirable gene segments with a functioning piece of replacement DNA--a process called homologous recombination.
Dr. Yang reported that these hybrid proteins could be constructed to locate specific segments of the DNA in any sort of organism. "This breakthrough could eventually make it possible to efficiently modify plant, animal and even human genomes,” said Dr. Yang. "It should be effective in a range of organisms.”
The proteins function by binding onto the specific segment of DNA the researcher needs to change. These proteins do this by reading the DNA sequence and finding the specific area to be cut. Once the protein binds onto the DNA at the correct spot, the other half of the protein then cuts the double-stranded DNA. Bad or undesirable DNA can be resected and good or more desirable DNA can be introduced. When the DNA heals, the good DNA is included in the gene.
Dr. Yang began his project approximately one year ago after seeing the results of research by Dr. Adam Bogdanove, ISU associate professor of plant pathology, showing that TAL effectors use a very clear-cut code to bind to a specific DNA sequence. This discovery allowed Dr. Yang to predict precisely where the TAL effector nuclease will bind on the DNA to make the cut. Another study had similar results.
The conecept has also been validated by Dr. Bogdanove and Dr. Dan Voytas, collaborator in genetics, development, and cell biology at Iowa State, and director of the Center for Genome Engineering at the University of Minnesota (Twin Cities, USA). The TAL effector-nuclease approach improves on tools currently available for genome modification. It should be faster and less expensive to make TAL effector nucleases, and simpler to design them to recognize specific DNA sequences, according to Dr. Yang.
Yang's findings appeared in August 2010 in the online version of the journal Nucleic Acids Research. Dr. Voytas' and Bogdanove's study also appeared in August 2010 the journal Genetics. Dr. Voytas and Dr. Bogdanove were also able to demonstrate that the TAL effector part of the hybrid protein can be modified to target new DNA sequences.
Related Links:
Iowa State University
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Mass Spectrometry Metabolomics Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
Blood-based assays are increasingly used to detect and monitor cancer, but many require relatively high fractions of circulating tumor DNA, limiting their utility when disease burden is low.... Read more
AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
Liquid biopsy is increasingly used to guide targeted therapy by detecting tumor-derived mutations in blood, but distinguishing true tumor signals from background noise remains challenging.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








